ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,307.39
-0.01%
Dow Jones
39,796.55
-0.03%
US Dollar vs MXN
16.65729
0.62%
Brent Oil
82.81
-0.86%
Bitcoin
69,700.00
-2.45%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aura Biosciences Inc (AURA)

  7. Aura Biosciences Inc (AURA) Noticias

AURA

Aura Biosciences (AURA)

Aura Biosciences Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AURA
FechaHoraFuenteTítuloSímboloCompañía
09/05/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AURAAura Biosciences Inc
09/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
09/05/202406:00GlobeNewswire Inc.Aura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
08/05/202406:00GlobeNewswire Inc.Aura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
27/03/202406:00Business WireAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
04/03/202416:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
02/02/202415:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
07/12/202307:00Business WireAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
09/11/202315:05Business WireAura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
07/11/202315:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AURAAura Biosciences Inc
06/11/202321:02Business WireAura Biosciences Announces Pricing of Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202315:08Business WireAura Biosciences Announces Proposed Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202314:50Dow Jones NewsAura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-SarNASDAQ:AURAAura Biosciences Inc
06/11/202314:00Business WireAura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
31/10/202315:05Business WireAura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023NASDAQ:AURAAura Biosciences Inc
23/10/202319:51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
02/10/202315:05Business WireAura Biosciences Strengthens and Expands Leadership Team with Key AppointmentsNASDAQ:AURAAura Biosciences Inc
09/08/202306:00Business WireAura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
09/06/202315:58Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AURAAura Biosciences Inc
07/06/202316:47Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:AURAAura Biosciences Inc
07/06/202315:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AURAAura Biosciences Inc
12/05/202306:00Business WireAura Biosciences to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:AURAAura Biosciences Inc
11/05/202315:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AURAAura Biosciences Inc
11/05/202315:10Business WireAura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
25/04/202315:07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AURAAura Biosciences Inc
25/04/202315:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AURAAura Biosciences Inc
15/03/202315:48Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AURAAura Biosciences Inc
15/03/202315:38Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AURAAura Biosciences Inc
15/03/202315:10Business WireAura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
16/02/202306:00Business WireAura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal AdministrationNASDAQ:AURAAura Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:AURA

Su Consulta Reciente

COIN
BTCUSD
Bitcoin
NASDAQ
MSFT
Microsoft
USOTC
RHHBY
Roche (QX)
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
NYSE
BAC
Bank of America
USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
NASDAQ
AAPL
Apple
NYSE
CVX
Chevron
NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
FX
EURMXN
Euro vs MXN
CCOM
US500
US 500
FX
EURUSD
Euro vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados